The MKLN1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, engineered to disrupt the MKLN1 gene locus. This product provides a heterogeneous pool of cells harboring targeted gene disruption, enabling functional loss-of-function studies of MKLN1 without clonal selection. The polyclonal format preserves biological diversity while effectively abolishing MKLN1 protein expression, serving as a robust model for investigating scaffold protein-mediated signaling networks in B-cell contexts. Researchers can exploit this system to interrogate MKLN1-dependent pathways in a disease-relevant cellular background, facilitating mechanistic dissection of pathways controlling immune cell behavior.
The Raji host cell line originates from a Burkitt lymphoma patient and is Epstein-Barr virus (EBV)-negative, expressing characteristic B-cell surface markers including CD19, CD20, and surface IgM. These cells are widely employed as a model for B-cell malignancies and humoral immunity due to their rapid proliferation and retention of antigen-presentation capabilities. The Burkitt lymphoma lineage endows Raji cells with activated NF-??B signaling and deregulated MYC expression, making them particularly susceptible to perturbations in scaffold-mediated signal integration. Consequently, Raji cells provide a pathophysiologically relevant platform for elucidating how MKLN1 coordinates extracellular cues to modulate malignant B-cell phenotypes.
MKLN1 encodes a scaffold protein that orchestrates signal transduction by bridging membrane receptor activation to intracellular effector pathways. Mechanistically, MKLN1 associates with TRAF2 and the IKK complex, facilitating IKK-gamma (NEMO)-dependent NF-??B p65 phosphorylation and subsequent transcriptional activation of pro-survival genes. This scaffold also regulates actin cytoskeleton dynamics through interactions with F-actin and Rho GTPases, notably RhoA and Rac1, thereby influencing cell adhesion, spreading, and migration. Upstream activation is triggered by TNF-alpha, B cell receptor stimulation, integrin engagement, and CD40 ligand, which converge on MKLN1 to integrate signals toward NF-??B and MAPK/ERK pathways. Through these interactions, MKLN1 governs focal adhesion turnover and cytoskeletal remodeling, positioning it as a central node linking extracellular stimuli to gene expression and morphological changes.
In the Raji B-cell lymphoma context, MKLN1 knockout provides critical insights into the molecular underpinnings of B-cell malignancies and autoimmune disorders. The loss of MKLN1 disrupts NF-??B-dependent survival signals, potentially sensitizing cells to apoptosis and altering their adhesive and migratory properties. Given the involvement of BCR signaling and CD40 engagement in lymphoma pathogenesis, this model enables detailed examination of how scaffold ablation affects downstream targets such as IKK complex activity, p65 nuclear translocation, and actin polymerization. Moreover, the interaction with beta-catenin hints at crosstalk with Wnt pathways, expanding the scope to study adhesion-linked transcription. This knockout system therefore serves as a versatile tool for dissecting the multifaceted contributions of MKLN1 to lymphomagenesis and immune dysregulation.
Typical applications of the MKLN1 Knockout Raji Polyclonal Cells span B cell lymphoma biology, cell adhesion and migration studies, and signal transduction mechanism analysis. Representative experimental approaches include Western blotting for phospho-p65 to assess NF-??B activation, NF-??B luciferase reporter assays for transcriptional activity, and flow cytometry for integrin and adhesion molecule expression. Functional studies often employ transwell migration assays, immunofluorescence staining of F-actin to visualize cytoskeletal organization, and co-immunoprecipitation to verify MKLN1 interaction with TRAF2 or IKK-gamma. These cells also facilitate drug candidate screening targeting NF-??B or migration, such as testing proteasome inhibitors, and can be integrated into apoptosis assays. For further technical details, please contact Ascent Research.
